Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Falchook, Gerald Steven, McKean, Meredith, Kelly, William Kevin · Journal of Clinical Oncology · 2024